Selank: Research Overview, Tuftsin Analog Mechanism and Handling

Selank is a synthetic heptapeptide, a chain of seven amino acids, derived from tuftsin, a short peptide naturally associated with immune function. It was developed to extend the stability of tuftsin while exploring effects on the central nervous system, and it has been studied in preclinical models of anxiety-related behavior, cognition and immune signaling. PRIME supplies Selank as a research material for laboratory use only.

What is Selank?

Selank has the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). The first four residues, Thr-Lys-Pro-Arg, are the sequence of tuftsin, a tetrapeptide fragment of the heavy chain of immunoglobulin G that has been studied for its effects on immune cells such as macrophages. The added Pro-Gly-Pro tail is a motif used to make short peptides more resistant to enzymatic breakdown, since unmodified tuftsin is degraded rapidly.

Selank was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, and most of the published research on it comes from Russian research groups. It is closely related in design to Semax, another peptide from the same research tradition that uses the same Pro-Gly-Pro stabilizing extension on a different parent sequence.

In the United States, Selank is a research compound. It is not an approved medicine, and research-grade material is not intended for human use.

How Selank works: mechanism studied in research

The mechanism of Selank is not fully defined, and published work points to several overlapping systems rather than one receptor. The main lines of investigation are:

• GABAergic signaling: studies have suggested that Selank may influence the GABA system, including effects on the expression of genes linked to GABAergic neurotransmission and proposed allosteric interactions with GABA-A receptors. This is one reason it is often discussed alongside anxiolytic research.
• Enkephalin metabolism: Selank has been reported to inhibit enzymes that break down enkephalins, endogenous opioid peptides involved in stress and pain signaling, which could prolong their activity in experimental systems.
• Monoamines: animal studies have examined changes in serotonin and other monoamine levels in brain regions after Selank administration.
• Neurotrophic factors: research in rodents has looked at the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus, a factor associated with neuronal plasticity.
• Immune signaling: in keeping with its tuftsin origin, Selank has been studied for effects on cytokine expression, including interleukin-6, and other immune markers.

Because these observations come mostly from animal and cell studies, researchers generally regard Selank as a multi-target peptide whose primary mechanism is still under investigation.

Areas of research

• Anxiety-related behavior: Selank has been studied in rodent models of anxiety and stress, using standard behavioral tests.
• Learning and memory: animal studies have examined performance in memory and learning tasks.
• Gene expression in the brain: research has profiled changes in the expression of genes related to neurotransmission after exposure to Selank.
• Immunomodulation: its tuftsin-derived sequence has made it a subject of research on cytokine balance and immune cell activity.
• Peptide stability design: Selank is also a case study in how a short C-terminal extension can stabilize a small bioactive peptide.

These findings are preclinical or come from limited regional research. They do not establish any effect in people.

When reading the Selank literature, it is worth noting that many studies were published in Russian-language journals and use behavioral models, strains and endpoints that differ from those common elsewhere. Independent replication outside the original research groups remains limited, so labs designing new work often include established reference compounds and well-defined controls to place their results in context.

Selank key facts

Handling and storage in the lab

Selank is shipped as a lyophilized powder, the most stable form for a short peptide. Store unopened vials refrigerated, or frozen for longer periods, sealed and protected from light and moisture. Let a cold vial come to room temperature before opening to reduce condensation.

For lab work, the powder is typically reconstituted with bacteriostatic water. Introduce the diluent slowly along the inside of the vial and swirl gently until dissolved rather than shaking. Once in solution, keep the vial refrigerated and away from light, label it with concentration and date, and avoid repeated freeze-thaw cycles. Short peptides can lose activity in solution over time, so plan experiments around fresh preparations where possible.

Wear gloves and eye protection and follow your institution's procedures for handling and disposing of research chemicals.

Quality and lab results

With short peptides, small differences in sequence or purity can change experimental outcomes. Every batch of Selank sold by PRIME is tested by an independent laboratory, and each certificate of analysis is published on the lab results page. Check that the COA matches your lot number before starting work and file it with your records.

Vial size and current batch information are listed on the Selank product page.

Related research

• Selank vs Semax: a direct comparison of the two Pro-Gly-Pro-stabilized peptides and the research questions each fits.
• Semax research guide: the ACTH-derived sister peptide studied in neurological research.
• DSIP research guide: another short neuropeptide studied in sleep and stress research.

Selank FAQ

For laboratory research use only. Not for human consumption. Not a drug, food or cosmetic.